hematological malignancies

NGeneBio Raises $11M

The company has also achieved a CE-IVD mark for its HemeAccuTest, which targets hematological malignancies.

The Cobas m 511 combines a cell counter, slide maker and stainer, and a digital morphology analyzer into one integrated solution.

McKesson will exclusively distribute Sysmex's XW-100 system, a CLIA-waived complete blood count diagnostic instrument starting in the spring. 

The Seoul-based company also recently raised $1.9 million in series B funding and is targeting between $7 million and $8 million to close the round.

Miraca provides subspecialty anatomic pathology services in gastroenterology, dermatology, hematology, breast health, and urology.

The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.

The firms will develop tests in the hematology oncology space where detecting large structural variations of the genome is crucial for accurate diagnoses. 

The two companies are expanding a long-term collaboration to include development and commercialization of assays for the Applied Biosystems 3500Dx system.

The launch of the cobas m 511 system marks Roche's entry into the hematology space.